Key statistics
On Friday, Immatics NV (4A3:FRA) closed at 5.08, 64.56% above the 52 week low of 3.08 set on Apr 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.08 |
---|---|
High | 5.08 |
Low | 5.08 |
Bid | 5.04 |
Offer | 5.17 |
Previous close | 4.98 |
Average volume | 2.84k |
---|---|
Shares outstanding | 121.55m |
Free float | 83.52m |
P/E (TTM) | -- |
Market cap | 725.65m USD |
EPS (TTM) | -0.2557 USD |
Data delayed at least 15 minutes, as of Jul 11 2025 07:04 BST.
More ▼
- Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
- Immatics Announces First Quarter 2025 Financial Results and Business Update
- Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
- Immatics Announces Full Year 2024 Financial Results and Business Update
- Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
- Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
- Immatics Announces Pricing of $150 Million Public Offering
- Immatics Announces Proposed $150 Million Public Offering
- Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
- Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
More ▼